ZATLOUKAL, Petr, Luboš PETRUŽELKA, Milada ZEMANOVÁ, Vítězslav KOLEK, Jana SKŘIČKOVÁ, Miloš PEŠEK, Hana FOITŮ, Ivona GRYGÁRKOVÁ, Dimka SIXTOVÁ and Jaromír ROUBEC. Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial. Lung Cancer. 2003, vol. 41, No 3, p. 245-367, 22 pp. ISSN 0169-5002.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Gemcitabine plus cisplain vs. gecitabine plus carboplatin in stage IIIb and IV non small cell lung cancer: A phase III randomized trial
Authors ZATLOUKAL, Petr (203 Czech Republic), Luboš PETRUŽELKA (203 Czech Republic), Milada ZEMANOVÁ (203 Czech Republic), Vítězslav KOLEK (203 Czech Republic), Jana SKŘIČKOVÁ (203 Czech Republic, guarantor), Miloš PEŠEK (203 Czech Republic), Hana FOITŮ (203 Czech Republic), Ivona GRYGÁRKOVÁ (203 Czech Republic), Dimka SIXTOVÁ (203 Czech Republic) and Jaromír ROUBEC (203 Czech Republic).
Edition Lung Cancer, 2003, 0169-5002.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.798
RIV identification code RIV/00216224:14110/03:00009445
Organization unit Faculty of Medicine
Keywords in English non small cell lung cancer; gemcitabine; carboplatin; cisplatin; phase III trial
Tags Carboplatin, cisplatin, Gemcitabine, phase III trial
Changed by Changed by: prof. MUDr. Jana Skřičková, CSc., učo 1808. Changed: 19/1/2004 10:54.
Abstract
The randomized multicenter trial was conducted to compare the tolerability of gemcitabine plus cisplatin GP vs. gemcitabine plus carboplatin GC in chemonaive stage IIIb and IV pts. The enrolled pts, 87 in the GP branch and 89 in GC branch, were balanced demographically and for disease characteristics. Results show that that both regimens were comparable. GC may offer acceptable option for patients unable to receive cisplatin.
Links
MSM 141100003, plan (intention)Name: Zevní prostředí - karcinogeneze - onkologie
Investor: Ministry of Education, Youth and Sports of the CR, Environment - carcinogenesis - oncology
PrintDisplayed: 19/9/2024 21:42